We are live on ! Find out more
IDXX icon

Idexx Laboratories

511.65 USD
+5.17
1.02%
At close Updated Sep 18, 4:00 PM EDT
Pre-market
After hours
514.00
+2.35
0.46%
1 day
1.02%
5 days
0.16%
1 month
-7.53%
3 months
-8.97%
6 months
-11.34%
Year to date
-23.63%
1 year
-21.95%
5 years
-22.45%
10 years
362.45%
 

About: Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.

Employees: 11,000

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 52.8%
Neutral 41.7%
Negative 5.6%
Positive
Zacks Investment Research
1 day ago
IDEXX Stock Gains Following the Acquisition of CoVet
IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.
IDEXX Stock Gains Following the Acquisition of CoVet
Neutral
Business Wire
1 day ago
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm detection for broader intestinal parasite screening.
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
Neutral
Business Wire
2 days ago
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX announces acquisition of CoVetAI to advance veterinary workflow intelligence.
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
Neutral
Seeking Alpha
4 days ago
IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Positive
Seeking Alpha
8 days ago
Baron Partners Fund Q2 2026 Contributors And Detractors
Baron Partners Fund performed very well in the second quarter, gaining 16.61% (Institutional Shares). Top contributors include Space Exploration Technologies, Tesla, Red Rock Resorts, Hyatt Hotels and Birkenstock Holding. Top detractors include CoStar Group, Gartner, Guidewire Software, Morningstar and IDEXX Laboratories.
Baron Partners Fund Q2 2026 Contributors And Detractors
Neutral
The Motley Fool
8 days ago
Insider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of Stock
The transaction involved 2,203 shares at $532.08 per share for a total value of ~$1.2 million. The director traded shares equal to 23% of the stake held before the filing.
Insider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of Stock
Negative
Zacks Investment Research
15 days ago
Idexx (IDXX) Down 7.8% Since Last Earnings Report: Can It Rebound?
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?
Idexx (IDXX) Down 7.8% Since Last Earnings Report: Can It Rebound?
Positive
Seeking Alpha
15 days ago
Baron Focused Growth Fund Q2 2026 Portfolio Update
Baron Focused Growth Fund rebounded in Q2 from a disappointing start to the year, with the Fund gaining 13.26% compared with a gain of 24.02% for the Russell 2500 Growth Index. We remain steadfast in our commitment to long-term investing in competitively advantaged, growth businesses. As of June 30, 2026, the Fund owned 28 investments.
Baron Focused Growth Fund Q2 2026 Portfolio Update
Neutral
Business Wire
18 days ago
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am – 11:20 am (ET). A live audio webcast of the fireside chat will be available through.
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
Positive
Zacks Investment Research
18 days ago
Idexx Laboratories (IDXX) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Idexx Laboratories (IDXX) is a Top-Ranked Growth Stock: Should You Buy?
Price charts implemented using Lightweight Charts™